Although the evidence for PLEX in digoxin toxicity is limited to case reports and is not currently included in formal guidelines, our experience adds to the growing body of literature suggesting that PLEX may be a valuable intervention in Fab-refractory cases, especially when complicated by CKD and a large tissue digoxin burden [7,9]. This evidence concerns the gene FANCB and chronic kidney disease.